QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+early-stage breast cancer: Analyses from the ExteNET and CONTROL trials 会议论文 作者:  Delaloge, S.;  Hurvitz, S.;  Chan, N.;  Bose, R.;  Jankowitz, R. C. 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/05 Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: BOLERO-1 会议论文 作者:  Hurvitz, Sara A.;  Andre, Fabrice;  Jiang, Zefei;  Shao, Zhimin;  Neciosup, Silvia P. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/19 MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC) 会议论文 作者:  Im, S. -A.;  Chow, L.;  Shao, Z.;  Tripathy, D.;  Bardia, A. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19 Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial 期刊论文 LANCET ONCOLOGY, 2015, 卷号: 16, 期号: 7 作者:  Hurvitz, Sara A.;  Andre, Fabrice;  Jiang, Zefei;  Shao, Zhimin;  Mano, Max S. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment 期刊论文 2012, 卷号: 72 作者:  Xu, B.;  Im, S-A;  Huang, C-S;  Im, Y-H;  Ro, J. 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13